TESARO (TSRO) Misses Q3 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
TESARO Announces Third-Quarter 2015 Operating Results
October 29, 2015 4:06 PM EDTVARUBI (oral rolapitant) approved by U.S. FDA; commercial launch planned for mid-November VARUBI added to National Comprehensive Cancer Network (NCCN) Antiemesis Guidelines with a Category 1 Level of Evidence and Consensus Patient treatment continues in the Phase 3 NOVA trial of niraparib; based upon the observed event rate, top-line data is now anticipated to become available in Q2 2016 Clinical trials for anti-PD-1 and anti-TIM-3 antibody candidates planned to initiate in 1H 2016 Cash and cash equivalents totaled $302.5 million as of September 30, 2015
WALTHAM, Mass., Oct. 29, 2015 (GLOBE NEWSWIRE) --... More
TESARO Announces Third-Quarter 2015 Operating Results
October 29, 2015 4:06 PM EDTVARUBI (oral rolapitant) approved by U.S. FDA; commercial launch planned for mid-November VARUBI added to National Comprehensive Cancer Network (NCCN) Antiemesis Guidelines with a Category 1 Level of Evidence and Consensus Patient treatment continues in the Phase 3 NOVA trial of niraparib; based upon the observed event rate, top-line data is now anticipated to become available in Q2 2016 Clinical trials for anti-PD-1 and anti-TIM-3 antibody candidates planned to initiate in 1H 2016 Cash and cash equivalents totaled $302.5 million as of September 30, 2015
WALTHAM, Mass., Oct. 29, 2015 (GLOBE NEWSWIRE) --... More
